Navigation Links
BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
Date:3/4/2008

BIRMINGHAM, Ala., March 4 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the fourth quarter and year ended December 31, 2007.

"In 2007, we gained greater clarity in terms of the progress made in each of our lead product programs, peramivir, forodesine HCl and BCX-4208," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "Each program is now either in mid-stage clinical testing or, in the case of forodesine HCl, a pivotal trial. Over the course of the year, we have assembled a strong management team to execute on our commitments and advance our product candidates in 2008."

Fourth Quarter 2007 Financial Results

The Company reported revenues of $28.2 million in the fourth quarter of 2007, compared to $2.1 million in the fourth quarter of 2006. The increase in revenues is due to revenue from the contract with the U.S. Department of Health and Human Services ("HHS") for the development of peramivir, a $7.0 million milestone payment received from Shionogi & Co., Ltd., and the continuing amortization of deferred revenue from our collaborative agreements.

The net loss for the quarter ended December 31, 2007 was $2.3 million, or $0.06 per share, compared to a net loss of $10.1 million, or $0.34 per share, for the quarter ended December 31, 2006.

Research and development ("R&D") expenses were $29.1 million in the fourth quarter of 2007, compared to $11.2 million in the fourth quarter of 2006. The increase in R&D expenses is primarily attributable to an increase in clinical trial related expenses, manufacturing costs for our lead product candidates and costs related to an increase in the personnel supporting the advanced development of our pro
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
2. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
5. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
6. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
8. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
9. Genetic Engineering & Biotechnology News reports on advances in miRNA
10. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
11. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... On April 19th the Center for Disease ... the growing antibiotic resistant bacteria that may be lurking ... study were released late last month showing higher antibiotic ... years. For those suffering from bacteria driven acne, Probiotic ... in food, may eventually help breed acne causing bacteria. ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Expression Genetics, Inc.,(EGEN) announced today that ... selected as one of the Top 10 ... strategic partnering. The selection was made by,an ... leading,provider of business information products and services ...
... Development Efforts, SALT LAKE CITY, Sept. 5 ... development of molecular diagnostic and motion preserving,technologies in ... Ross has,joined the executive management team as the ... this new role, Ross will oversee Axial Biotech,s ...
... Ind., Sept. 4 Zimmer Holdings, Inc.,(NYSE: ZMH ... have,agreed to acquire the Abbott Spine business from Abbott ... to fund the purchase price,from cash on hand and ... expected to close in the fourth quarter of 2008. ...
Cached Biology Technology:Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 2Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 3Axial Biotech appoints new Vice President of Strategic Initiatives 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 3Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 4
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
(Date:5/22/2013)... discovery of potential environmental and human health effects ... each year has led scientists to recommend stronger ... of lithium-ion (Li-ion) battery materials. That,s the conclusion ... Environmental Science & Technology . , Oladele ... batteries have become mainstays for powering everything from ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... forests that add the most new growth each year -- ... Survey (USGS) study published in a recent issue of the ... forests will respond to ongoing and future environmental changes. , ... world¹s most productive forests may be those likely to respond ...
... DuPont polymer derived from a biological source, has been ... China Central Television (CCTV) as "Most Visionary Innovation" at ... DuPontTM Sorona® will receive the 2005 "New ... Global Plastics and Environmental Conference, sponsored by the Society ...
... core cellular mechanisms of sleep, researchers at University of ... a single gene mutation that has a powerful effect ... In its normal state, the Drosophila (fruit fly) gene, ... flow of potassium into cells, a process that critically ...
Cached Biology News:Live fast, die young true for forests too 2DuPont's first biologically derived polymer receives global recognition 2Wisconsin researchers identify sleep gene 2Wisconsin researchers identify sleep gene 3Wisconsin researchers identify sleep gene 4
Mouse Axl MAb (Clone 175128)...
Mouse GDF-8 Propeptide Affinity Purified Polyclonal Ab...
... Allen (1995) This book contains ... on current issues relating to the aetiology ... advances have been made recently which greatly ... include molecular neuropathology through clinical and diagnostic ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
Biology Products: